Live Breaking News & Updates on Rsv vaccine

Stay informed with the latest breaking news from Rsv vaccine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Rsv vaccine and stay connected to the pulse of your community

Pfizer to seek approval for RSV vaccine for people as young as 18

An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said in a news release Tuesday. The company said it would submit the information to the US Food and Drug Administration for potential expansion of the vaccine’s availability to people ages 18 to 59.

Annaliesa-anderson , Pfizer , Drug-administration , Rsv-vaccine , Fizer , Lder-adults , Accine-research-and-development , S-food-and-drug-administration ,

Pfizer: RSV Vaccine Could Protect Younger High-Risk Adults

Pfizer said the shot—approved for adults age 60 and older—had similar effects in adults over age 18.

Pfizer , Glaxosmithkline , Drug-administration , National-transportation-safety-board , Environmental-protection-agency , Rsv-vaccine , Rsv ,

Gsk: Rsv Vaccine, Arexvy, Accepted For Review By Health Canada F… -February 26, 2024 at 07:08 am EST

GSK: RSV VACCINE, AREXVY, ACCEPTED FOR REVIEW BY HEALTH CANADA FOR PREVENTION OF RSV DISEASE IN ADULTS AGED 50-59 AT INCREASED RISK
...

Canada , Reuters , Health-canada , Rsv-vaccine , Markets ,

What We're Reading: RSV Vaccine Approval Extension; Pharmacy Staffing Shortage; Downplaying Measles Dangers

The FDA has accepted GSK’s application for priority review for extended use of Arexvy in higher-risk adults aged 50 to 59 years; pharmacy retail chains are finding it harder to draw the next generation of pharmacists; antivaccine activists are falsely downplaying the dangers of measles amid global outbreaks.

Japan , Walgreens , European-union , What-we-x27-re-reading , Rsv-vaccine , Arexvy , Pharmacist-shortage , Measles , Anti-vaccine-movement ,

Doctors look ahead to next RSV season, hopeful shots will be more accessible

Health experts are now looking ahead to the next RSV season. They're hopeful that the new, preventative shots will be more accessible by the end of the year.

Jill-roberts , Juan-dumois , College-of-public-health , Vaccines-for-children-program , Pediatric-infectious-disease-physician , Johns-hopkins-all-children , Rsv , Respiratory-syncytial-virus , Shot , Treatment , Rsv-season , Rsv-shots

COVID, flu and RSV are still here. The 'tripledemic' doesn't care that we're over being sick.

An errant cough may lead to a sweet grandma whom you stood in line with at the grocery store dying in the hospital.

United-states , Americans , American , Centers-for-disease , World-health-organization , Disease-control , Rsv-vaccine , Sv , Etastatic-breast-cancer , Espiratory-viruses , Nfluenza

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER). The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy. The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 b

Emma-walmsley , Wikimedia-commons , Raises-over , Chief-executive-officer , Specialty-medicines , Stock-market-game , Benzinga-pro , Day-trial , Shingrix-vaccine-and-newly-launched , Rsv-vaccine , Sk-plc

Breakthrough RSV Vaccines for Infants, Seniors Face Uneven Uptake Amidst Supply Chain Woes

Explore the challenges and hopes surrounding breakthrough RSV vaccines, as infant immunization, elderly vaccination, and supply chain hurdles shape the uneven uptake of these game-changing tools against respiratory syncytial virus.

United-states , America , Allison-bartlett , Hugh-hastings-getty , Eric-biondi , Astrazeneca , Thermo-fisher , Johns-hopkins-children-center , University-of-chicago-medicine-comer-children-hospital , Hugh-hastings , Getty-images , Chicago-medicine-comer-children

More Than 150 Infants, Pregnant Women Given Incorrect RSV Vaccine, CDC Says

According to reports, there have been 25 cases of accidental administration of Pfizer (Abrsyvo) or GSK (Arexvy) RSV vaccines to children below two and 128 cases of mistaken administration of the GSK

Nirsevimab-beyfortus , Centers-for-disease , Disease-control , Respiratory-syncytial-virus , Adverse-event-reporting-system , Pfizer-abrysvo , Us-world , Rsv-vaccine , Incorrect-vaccine , Pregnant-women , Young-children , Cdc-warns

'It's very scary': WNY parents & pediatricians deal RSV vaccine shortage

There is a critical shortage of the RSV vaccine for children leaving pediatricians in a struggle to give the shots and parents worried about the health of their child.

Orchard-park , New-york , United-states , Dana-owczarczak , Colleen-mattimore , Reese-owczarczak , Chuck-schumer , Buckley , Orchard-park-monday , Respiratory-syncytial , Senator-schumer , Western-new-york